A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma

• Published in: Clinical cancer research Vol. 28; no. 18; pp. 3950 - 3957
• Main Authors: Saulnier-Sholler, Giselle, Duda, Dan G., Bergendahl, Genevieve, Ebb, David, Snuderl, Matija, Laetsch, Theodore W., Michlitsch, Jennifer, Hanson, Derek, Isakoff, Michael S., Bielamowicz, Kevin, Kraveka, Jacqueline M., Ferguson, William, Carmeliet, Peter, De Deene, A., Gijsen, Lore, Jain, Rakesh K.
• Format: Journal Article
• Language: English
• Published: United States 15.09.2022
• Subjects: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Cerebellar Neoplasms; Child; Female; Humans; Maximum Tolerated Dose; Medulloblastoma - drug therapy; Medulloblastoma - pathology; Neuroblastoma - drug therapy; Placenta Growth Factor; Rhabdomyosarcoma, Alveolar; Sarcoma, Ewing

Placental growth factor (PlGF) and its receptor neuropilin 1 are elevated in malignant embryonal tumors and mediate tumor progression by promoting cell proliferation, survival, and metastasis. TB-403 is a blocking monoclonal antibody against PlGF that inhibits tumor growth and increases survival in...